Published in Proc Natl Acad Sci U S A on February 24, 2004
Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum. BMC Genomics (2009) 2.50
Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci U S A (2004) 1.40
Activity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channels. Proc Natl Acad Sci U S A (2007) 1.17
A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem (2010) 1.09
Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr Purif (2010) 1.05
Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon (2010) 1.04
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) (2012) 1.04
Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry (2005) 1.02
Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol (2008) 1.00
A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem (2010) 0.99
Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One (2012) 0.98
Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A (2010) 0.94
Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells. PLoS One (2014) 0.92
Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem (2011) 0.91
Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) (2011) 0.88
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
The zinc-dependent protease activity of the botulinum neurotoxins. Toxins (Basel) (2010) 0.84
Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells. Toxins (Basel) (2010) 0.81
A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate. Proc Natl Acad Sci U S A (2006) 0.81
Persistence of Botulinum neurotoxin inactivation of nerve function. Curr Top Microbiol Immunol (2013) 0.78
Development of a Cell-Based Functional Assay for the Detection of Clostridium botulinum Neurotoxin Types A and E. Int J Microbiol (2013) 0.77
Emerging opportunities for serotypes of botulinum neurotoxins. Toxins (Basel) (2012) 0.77
From GFP to β-lactamase: advancing intact cell imaging for toxins and effectors. Pathog Dis (2015) 0.76
Unexpected transcellular protein crossover occurs during canonical DNA transfection. J Cell Biochem (2014) 0.75
Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain. Sci Rep (2017) 0.75
A Highly Specific Monoclonal Antibody for Botulinum Neurotoxin Type A-Cleaved SNAP25. Toxins (Basel) (2015) 0.75
Septins: Regulators of Protein Stability. Front Cell Dev Biol (2016) 0.75
Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol (1978) 13.02
The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci U S A (1996) 6.51
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (1993) 5.73
Neurotoxins affecting neuroexocytosis. Physiol Rev (2000) 5.42
A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell (1992) 4.39
Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol (1998) 4.21
Adaptors for clathrin-mediated traffic. Annu Rev Cell Dev Biol (1999) 3.47
Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci (2002) 3.33
Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol (2000) 3.31
Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem (1994) 2.59
A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr Biol (1998) 2.50
Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci U S A (1998) 2.50
A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol (1998) 2.43
Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol (2003) 2.19
Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon (2001) 2.05
Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol (1999) 1.98
How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie (2000) 1.90
Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem (2002) 1.86
Role of tetanus neurotoxin insensitive vesicle-associated membrane protein (TI-VAMP) in vesicular transport mediating neurite outgrowth. J Cell Biol (2000) 1.82
Genetic analyses of adaptin function from yeast to mammals. Gene (2002) 1.70
Acidic di-leucine motif essential for AP-3-dependent sorting and restriction of the functional specificity of the Vam3p vacuolar t-SNARE. J Cell Biol (1998) 1.58
The Di-leucine motif of vesicle-associated membrane protein 4 is required for its localization and AP-1 binding. J Biol Chem (2001) 1.57
Identification of an axonal determinant in the C-terminus of the sodium channel Na(v)1.2. EMBO J (2001) 1.54
The residues Leu(Ile)475-Ile(Leu, Val, Ala)476, contained in the extended carboxyl cytoplasmic tail, are critical for targeting of the resident lysosomal membrane protein LIMP II to lysosomes. J Biol Chem (1994) 1.44
An evolutionarily conserved dileucine motif in Shal K+ channels mediates dendritic targeting. Nat Neurosci (2003) 1.38
Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett (1999) 1.36
A single internalization signal from the di-leucine family is critical for constitutive endocytosis of the type II TGF-beta receptor. J Cell Sci (2001) 1.31
Identification of an insulin-responsive, slow endocytic recycling mechanism in Chinese hamster ovary cells. J Biol Chem (1998) 1.24
Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci (2003) 1.21
Di-leucine signals mediate targeting of tyrosinase and synaptotagmin to synaptic-like microvesicles within PC12 cells. Mol Biol Cell (1999) 1.19
A leucine-based motif mediates the endocytosis of vesicular monoamine and acetylcholine transporters. J Biol Chem (1998) 1.13
Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Trends Cell Biol (1999) 1.09
Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett (1998) 1.08
Moving the insulin-regulated glucose transporter GLUT4 into and out of storage. Trends Cell Biol (2001) 1.06
Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon (2001) 1.04
Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon (2002) 1.00
Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. FEBS Lett (1997) 0.93
Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Protein Expr Purif (2000) 0.93
Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie (2000) 0.92
The cytoplasmic tail of the vesicular acetylcholine transporter contains a synaptic vesicle targeting signal. J Biol Chem (1998) 0.92
Phosphorylation of human gp130 at Ser-782 adjacent to the Di-leucine internalization motif. Effects on expression and signaling. J Biol Chem (2000) 0.89
Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present. Biochemistry (1997) 0.85
Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. Toxicon (2001) 0.83
Other noncosmetic uses of BOTOX. Semin Cutan Med Surg (2001) 0.77
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA (2003) 6.24
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI Series. Implement Sci (2008) 3.64
Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med (2009) 2.40
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A (2009) 2.31
ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res (2011) 2.03
Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension (2008) 2.00
Brain microglial cytokines in neurogenic hypertension. Hypertension (2010) 1.97
Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem (2004) 1.88
Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem (2002) 1.86
Mammalian nucleoside transporters. Curr Drug Metab (2004) 1.75
Role of proinflammatory cytokines and redox homeostasis in exercise-induced delayed progression of hypertension in spontaneously hypertensive rats. Hypertension (2009) 1.74
Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med (2013) 1.71
Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res (2009) 1.70
The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med (2010) 1.64
Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol (2005) 1.63
Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos (2007) 1.60
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol (2008) 1.59
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther (2003) 1.56
Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure. Am J Physiol Heart Circ Physiol (2005) 1.55
Advancing evidence-based care for diabetes: lessons from the Veterans Health Administration. Health Aff (Millwood) (2007) 1.53
Use of MR cell tracking to evaluate targeting of glial precursor cells to inflammatory tissue by exploiting the very late antigen-4 docking receptor. Radiology (2012) 1.51
Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB. Cardiovasc Res (2008) 1.44
TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol. Am J Physiol Heart Circ Physiol (2007) 1.39
TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats. Am J Physiol Heart Circ Physiol (2007) 1.37
Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci (2009) 1.37
Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol (2008) 1.37
NF-kappaB-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res (2009) 1.35
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension (2010) 1.35
Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther (2010) 1.34
Angiotensin II-induced hypertension is modulated by nuclear factor-κBin the paraventricular nucleus. Hypertension (2011) 1.33
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension (2009) 1.32
Heart failure and the brain: new perspectives. Am J Physiol Regul Integr Comp Physiol (2003) 1.30
Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol (2003) 1.30
Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. Eur J Heart Fail (2008) 1.28
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A (2008) 1.27
Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative. J Gen Intern Med (2010) 1.25
Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochem Pharmacol (2006) 1.24
Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR. Basic Res Cardiol (2011) 1.24
The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol (2002) 1.23
Brain tumour necrosis factor-alpha modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure. Cardiovasc Res (2009) 1.21
Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol (2006) 1.17
Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. Physiol Behav (2005) 1.16
Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol (2009) 1.15
Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. PLoS One (2013) 1.15
The Nlrp3 inflammasome promotes age-related thymic demise and immunosenescence. Cell Rep (2012) 1.14
Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int (2007) 1.12
Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family. J Biol Chem (2006) 1.10
TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction. Free Radic Biol Med (2008) 1.10
Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene (2003) 1.10
Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos (2010) 1.09
Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord (2011) 1.09
Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem (2008) 1.08
Tumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol (2008) 1.08
Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep (2010) 1.05
Inflammation and oxidative stress are elevated in the brain, blood, and adrenal glands during the progression of post-traumatic stress disorder in a predator exposure animal model. PLoS One (2013) 1.05
Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon (2003) 1.04
Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease. Nat Genet (2006) 1.03
Central TNF inhibition results in attenuated neurohumoral excitation in heart failure: a role for superoxide and nitric oxide. Basic Res Cardiol (2011) 1.02
Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord (2004) 1.01
Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics (2003) 1.01
Diagnosis of common dermopathies in dialysis patients: a review and update. Semin Dial (2012) 1.00
Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL. Obesity (Silver Spring) (2009) 1.00
Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol (2008) 1.00
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol (2006) 1.00
Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One (2012) 0.98
Aging is associated with hypoxia and oxidative stress in adipose tissue: implications for adipose function. Am J Physiol Endocrinol Metab (2011) 0.97
A blueberry-enriched diet attenuates nephropathy in a rat model of hypertension via reduction in oxidative stress. PLoS One (2011) 0.97
(Pro)renin receptor mediates both angiotensin II-dependent and -independent oxidative stress in neuronal cells. PLoS One (2013) 0.97
Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. PLoS One (2008) 0.96
Expression profiling of the solute carrier gene family in the mouse brain. J Pharmacol Exp Ther (2009) 0.96
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer Chemother Pharmacol (2011) 0.95
Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. Am J Physiol Renal Physiol (2009) 0.95
Chronic exercise preserves renal structure and hemodynamics in spontaneously hypertensive rats. Antioxid Redox Signal (2011) 0.94
Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J (2012) 0.94
A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients. Cancer Chemother Pharmacol (2008) 0.93
Infection of cardiomyocytes and induction of left ventricle dysfunction by neurovirulent polytropic murine retrovirus. J Virol (2007) 0.93
Evidence for CRHR1 in multiple sclerosis using supervised machine learning and meta-analysis in 12,566 individuals. Hum Mol Genet (2010) 0.93
Depolarization after resonance energy transfer (DARET): a sensitive fluorescence-based assay for botulinum neurotoxin protease activity. Anal Biochem (2011) 0.92
Angiotensin II causes imbalance between pro- and anti-inflammatory cytokines by modulating GSK-3β in neuronal culture. Br J Pharmacol (2013) 0.92
Aryl hydrocarbon exposure induces expression of MMP-9 in human prostate cancer cell lines. Cancer Lett (2004) 0.92
Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther (2010) 0.91
Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog (2013) 0.91
Involvement of tumor necrosis factor-alpha in natriuretic response to systemic infusion of nitric oxide synthase inhibitor in anesthetized mice. Am J Physiol Renal Physiol (2010) 0.91
Paraventricular nucleus corticotrophin releasing hormone contributes to sympathoexcitation via interaction with neurotransmitters in heart failure. Basic Res Cardiol (2011) 0.90
Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. J Biol Chem (2012) 0.90